315 related articles for article (PubMed ID: 29055257)
1. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
McIntyre RS; Weiller E; Zhang P; Weiss C
J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
[TBL] [Abstract][Full Text] [Related]
3. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
Katzman MA; Therrien F; MacKenzie EM; Wang F; de Jong-Laird A; Boucher M
J Affect Disord; 2022 Nov; 316():201-208. PubMed ID: 35970327
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies.
Thase ME; Zhang P; Weiss C; Meehan SR; Hobart M
Expert Opin Pharmacother; 2019 Oct; 20(15):1907-1916. PubMed ID: 31290344
[No Abstract] [Full Text] [Related]
9. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
[TBL] [Abstract][Full Text] [Related]
12. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
[TBL] [Abstract][Full Text] [Related]
13. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
[TBL] [Abstract][Full Text] [Related]
14. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
16. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
17. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
Krystal AD; Mittoux A; Meisels P; Baker RA
Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
[TBL] [Abstract][Full Text] [Related]
19. Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.
McIntyre RS; Therrien F; Ismail Z; Meehan SR; Miguelez M; Larsen KG; Chen D; MacKenzie EM; Thase ME
J Psychiatr Res; 2023 Jun; 162():71-78. PubMed ID: 37099968
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
